AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8627059 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) monotherapy
Number of subjects: 73
Study 8627059 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 73
Study 1307608 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-probe assay using the Gen-probe kit
Number of subjects: 32
Study 1307608 — intervention group
Group type: COMPARATOR
Intervention: Serological tests (complement fixation and passive hemagglutination tests)
Number of subjects: 32
Study 1307608 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-probe assay
Number of subjects: 32
Study 6486240 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Coordinated team of allied health professionals (AHPs) evaluated regularly
Number of subjects: 23
Study 6486240 — intervention group
Group type: COMPARATOR
Intervention: Comparison Group (CG) - AHPs seen only upon referral
Number of subjects: 23
Study 6486240 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Grip strength improvement
Number of subjects: 23
Study 6486240 — intervention group
Group type: COMPARATOR
Intervention: Comparison Group (CG) - Grip strength decrease
Number of subjects: 23
Study 6486240 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Hand range of motion
Number of subjects: 23
Study 6486240 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Finger flexion deformities
Number of subjects: 23
Study 6486240 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Positive attitudes
Number of subjects: 23
Study 31168999 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HHA) + Platelet Rich Plasma (PRP)
Number of subjects: 60
Study 31168999 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HHA)
Number of subjects: 60
Study 29420536 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate hydration (250 ml 1.4%)
Number of subjects: 333
Study 29420536 — intervention group
Group type: COMPARATOR
Intervention: Saline hydration (1000 ml 0.9%)
Number of subjects: 333
Study 29420536 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate hydration
Number of subjects: 333
Study 29420536 — intervention group
Group type: COMPARATOR
Intervention: Saline hydration
Number of subjects: 333
Study 27352285 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexis(®) O C‐Section Retractor
Number of subjects: 198
Study 27352285 — intervention group
Group type: COMPARATOR
Intervention: Collins self‐retaining metal retractor
Number of subjects: 198
Study 24797030 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal cerebellar transcranial direct current stimulation
Number of subjects: 10
Study 24797030 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 22613903 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 112
Study 22613903 — intervention group
Group type: COMPARATOR
Intervention: White light endoscopy (WLE)
Number of subjects: 112
Study 20722643 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose misoprostol 25 microg
Number of subjects: 171
Study 20722643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone 3 mg
Number of subjects: 171
Study 20722643 — intervention group
Group type: COMPARATOR
Intervention: Single-dose misoprostol
Number of subjects: 171
Study 18596716 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cord clamping (30 s)
Number of subjects: 64
Study 18596716 — intervention group
Group type: COMPARATOR
Intervention: Late cord clamping (3 min)
Number of subjects: 64
Study 16099292 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 250 microg
Number of subjects: 1411
Study 16099292 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg
Number of subjects: 1411
Study 16099292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1411
Study 11912072 — intervention group
Group type: EXPERIMENTAL
Intervention: MMT (Methadone Maintenance Treatment)
Number of subjects: 359
Study 11912072 — intervention group
Group type: COMPARATOR
Intervention: N-MMT (Non-Methadone Maintenance Treatment)
Number of subjects: 359
Study 10522982 — intervention group
Group type: EXPERIMENTAL
Intervention: Androderm testosterone transdermal system (TTD) - two 2.5-mg systems applied nightly
Number of subjects: 66
Study 10522982 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular testosterone enanthate (i.m.) - 200 mg injected every 2 weeks
Number of subjects: 66
Study 10522982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 66
Study 8706192 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms x kg(‐1), n = 25)
Number of subjects: 100
Study 8706192 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg (n = 25)
Number of subjects: 100
Study 8706192 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg (n = 25)
Number of subjects: 100
Study 8706192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, n = 25)
Number of subjects: 100
Study 1703946 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous stimulation of bilateral median nerves
Number of subjects: 12
Study 1703946 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous stimulation of left median and left ulnar nerves
Number of subjects: 12
Study 7261688 — intervention group
Group type: EXPERIMENTAL
Intervention: Talampicillin (TMP) 325 mg (equivalent to 200 mg ampicillin)
Number of subjects: 30
Study 7261688 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (AMP) 500 mg
Number of subjects: 30
Study 7261688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 30
Study 31445091 — intervention group
Group type: EXPERIMENTAL
Intervention: vPTA (venous percutaneous transluminal angioplasty)
Number of subjects: 66
Study 31445091 — intervention group
Group type: COMPARATOR
Intervention: Control group (vPTA-not)
Number of subjects: 66
Study 30842057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 30842057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 28143919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor (CFTR potentiator)
Number of subjects: 83
Study 25911497 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurectomy
Number of subjects: 22
Study 25911497 — intervention group
Group type: COMPARATOR
Intervention: Neurolysis
Number of subjects: 22
Study 23791513 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐39220675
Number of subjects: 53
Study 23791513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 53
Study 23791513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 22211206 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (N=160) with phone contact from a registered nurse and clinical pharmacist, and psychiatrist supervision via video chats.
Number of subjects: 360
Study 22211206 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N=200)
Number of subjects: 360
Study 19890693 — intervention group
Group type: EXPERIMENTAL
Intervention: Local lidocaine injections during ESDs (mean dose 236 mg, mean volume 55.4 ml)
Number of subjects: 20
Study 19890693 — intervention group
Group type: COMPARATOR
Intervention: Conventional normal saline solution injections during ESDs (control group)
Number of subjects: 20
Study 19890693 — intervention group
Group type: EXPERIMENTAL
Intervention: Local lidocaine injections during ESDs (LG)
Number of subjects: 20
Study 17029975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 1500mg/day for 2 years
Number of subjects: 222
Study 15252821 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 56
Study 15252821 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 56
Study 10994156 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine glucuronate combined with diethanolamine glucuronate and nicotinamide ascorbate (Ietepar)
Number of subjects: 191
Study 10994156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 9305556 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 g in 500 ml NSaline)
Number of subjects: 41
Study 9305556 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NSaline)
Number of subjects: 41
Study 8285082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid containing aluminum hydroxide
Number of subjects: 0
Study 8285082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3543246 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU (1,000 mg/m2 days 1 through 4) with bolus FA (200 mg/m2 days 1 through 4) - infusion arm
Number of subjects: 125
Study 3543246 — intervention group
Group type: COMPARATOR
Intervention: 5-FU (325 mg/m2 days 1 through 5) with bolus FA (200 mg/m2 days 1 through 5) - bolus arm
Number of subjects: 125
Study 30946265 — intervention group
Group type: EXPERIMENTAL
Intervention: Known load 1RM trial
Number of subjects: 20
Study 30946265 — intervention group
Group type: COMPARATOR
Intervention: Unknown load 1RM trial
Number of subjects: 20
Study 29400070 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-based feedback
Number of subjects: 55
Study 29400070 — intervention group
Group type: COMPARATOR
Intervention: Control (no accelerometer-based feedback)
Number of subjects: 55
Study 26825109 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month Balance Training Programme
Number of subjects: 100
Study 26825109 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention beyond regular osteoporosis treatment)
Number of subjects: 100
Study 25809854 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy diet (primarily low-fat dairy)
Number of subjects: 47
Study 25809854 — intervention group
Group type: EXPERIMENTAL
Intervention: High red meat diet (lean red meat)
Number of subjects: 47
Study 25809854 — intervention group
Group type: COMPARATOR
Intervention: Control diet (neither red meat nor dairy)
Number of subjects: 47
Study 23079373 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mirabegron
Number of subjects: 0
Study 23079373 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mirabegron
Number of subjects: 0
Study 23079373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20627289 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-light cystoscopy and transurethral resection of bladder tumors (TURBT)
Number of subjects: 446
Study 20627289 — intervention group
Group type: COMPARATOR
Intervention: Standard cystoscopy and resection
Number of subjects: 446
Study 18226993 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (bisphosphonate group)
Number of subjects: 12
Study 18226993 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 17136293 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antihistamines
Number of subjects: 0
Study 17136293 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation antihistamines
Number of subjects: 0
Study 15078430 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg single dose vaginal tablet (VT)
Number of subjects: 88
Study 15078430 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 10% single dose vaginal cream (VC)
Number of subjects: 88
Study 15078430 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 150 mg single dose oral capsule (Diflucan)
Number of subjects: 88
Study 15078430 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg VT and Clotrimazole 10% VC
Number of subjects: 88
Study 15078430 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Clotrimazole and Fluconazole)
Number of subjects: 88
Study 15078430 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mycological recurrence
Number of subjects: 88
Study 11269778 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis (with recombinant tissue plasminogen activator)
Number of subjects: 44
Study 11269778 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PTCA with stent implantation
Number of subjects: 44
Study 11269778 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 44
Study 9668994 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extraction of third molars
Number of subjects: 164
Study 9668994 — intervention group
Group type: COMPARATOR
Intervention: Retention of third molars
Number of subjects: 164
Study 8001522 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin intake (average daily intake above 0.5 mg/1000 kcal)
Number of subjects: 60
Study 8001522 — intervention group
Group type: EXPERIMENTAL
Intervention: EGRAC measurement (functional test for riboflavin status)
Number of subjects: 60
Study 3275601 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Number of subjects: 40
Study 3275601 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 40
Study 29903900 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline log-transformed suPAR
Number of subjects: 0
Study 29903900 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline log-transformed suPAR in patients with two APOL1 risk alleles
Number of subjects: 0
Study 28414008 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory nutrition promotion (CPNP) programme
Number of subjects: 876
Study 25236783 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin measurements at baseline
Number of subjects: 949
Study 24047591 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitacre needle
Number of subjects: 1376
Study 24047591 — intervention group
Group type: COMPARATOR
Intervention: Quincke needle
Number of subjects: 1376
Study 20972346 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrust joint manipulation (TJM) to the lumbar spine
Number of subjects: 35
Study 20972346 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation treatment
Number of subjects: 35
Study 18438113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate‐based bioresorbable membrane (Seprafilm)
Number of subjects: 150
Study 17136692 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus an experimental aortic catheter
Number of subjects: 1117
Study 17136692 — intervention group
Group type: COMPARATOR
Intervention: Standard CABG
Number of subjects: 1117
Study 12904634 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical velocity (vcrit)
Number of subjects: 34
Study 12904634 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic distance capacity (ADC)
Number of subjects: 34
Study 12904634 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance limit (dlim) and time limit (tlim) relationship
Number of subjects: 34
Study 10691822 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic laser ablation of the prostate (ELAP)
Number of subjects: 151
Study 10691822 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 151
Study 9084065 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral adinazolam mesylate SR tablets
Number of subjects: 39
Study 9084065 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg parenteral (i.v.) adinazolam mesylate
Number of subjects: 39
Study 9084065 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg i.v. NDMAD
Number of subjects: 39
Study 9084065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8441129 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (.05%)
Number of subjects: 79
Study 8441129 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (2%)
Number of subjects: 79
Study 8441129 — intervention group
Group type: COMPARATOR
Intervention: Progesterone (2%)
Number of subjects: 79
Study 8441129 — intervention group
Group type: COMPARATOR
Intervention: Cream based preparation
Number of subjects: 79
Study 3538742 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile insulin infusion (1 1/2 to 2 1/4 min pulses followed by 10 1/2 to 9 3/4 min intervals)
Number of subjects: 8
Study 3538742 — intervention group
Group type: COMPARATOR
Intervention: Continuous insulin infusion (0.45 mU/kg X min)
Number of subjects: 8
Study 30577730 — intervention group
Group type: COMPARATOR
Intervention: Self-affirmation
Number of subjects: 128
Study 30577730 — intervention group
Group type: COMPARATOR
Intervention: Moderately-severe health warnings
Number of subjects: 128
Study 30577730 — intervention group
Group type: COMPARATOR
Intervention: Highly-severe health warnings
Number of subjects: 128
Study 27171969 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Furosemide
Number of subjects: 0
Study 27171969 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroids
Number of subjects: 0
Study 24882604 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video in Spanish
Number of subjects: 20
Study 21556816 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training 3×/week for 16 weeks
Number of subjects: 26
Study 21556816 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training 3×/week for 16 weeks
Number of subjects: 26
Study 21556816 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence to training (≥75% attendance, n = 8)
Number of subjects: 26
Study 21556816 — intervention group
Group type: COMPARATOR
Intervention: Lower adherence to training (<75% attendance, n = 10)
Number of subjects: 26
Study 21098442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab (0.25 mg/kg)
Number of subjects: 534
Study 21098442 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab (0.25 mg/kg)
Number of subjects: 534
Study 18950458 — intervention group
Group type: EXPERIMENTAL
Intervention: DaunoXome (DNX) 80 mg/m(2) days 1‐3 plus cytarabine (AraC; 100 mg/m(2) days 1‐7)
Number of subjects: 301
Study 18950458 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (DNR) 45 mg/m(2) days 1‐3 plus cytarabine (AraC; 100 mg/m(2) days 1‐7)
Number of subjects: 301
Study 18950458 — intervention group
Group type: EXPERIMENTAL
Intervention: DaunoXome (DNX) after complete remission
Number of subjects: 301
Study 18950458 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (DNR) after complete remission
Number of subjects: 301
Study 18950458 — intervention group
Group type: EXPERIMENTAL
Intervention: DaunoXome (DNX) in long-term follow-up
Number of subjects: 301
Study 15899106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg co-administered with simvastatin 10mg or 20mg
Number of subjects: 418
Study 15899106 — intervention group
Group type: COMPARATOR
Intervention: Placebo co-administered with simvastatin 10mg or 20mg
Number of subjects: 418
Study 12730519 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded aerobic exercise programme
Number of subjects: 93
Study 12730519 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 93
Study 12730519 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 93
Study 11780237 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing combined with local application of 2% minocycline hydrochloride ointment (Periocline)
Number of subjects: 31
Study 11780237 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone (Control)
Number of subjects: 31
Study 8829939 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg intramuscularly (i.m.)
Number of subjects: 200
Study 8829939 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 30 mg intramuscularly (i.m.)
Number of subjects: 200
Study 8829939 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 50 mg orally
Number of subjects: 200
Study 8829939 — intervention group
Group type: COMPARATOR
Intervention: 2 mL NaCl i.m.
Number of subjects: 200
Study 1867962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cisapride 10 mg
Number of subjects: 20
Study 1867962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6833967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy training
Number of subjects: 0
Study 6833967 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium enemas accompanied by sigmoidoscopy
Number of subjects: 0
Study 6833967 — intervention group
Group type: EXPERIMENTAL
Intervention: All participating physicians
Number of subjects: 0
Study 31995688 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy (lansoprazole [30 mg], amoxicillin [1000 mg], and clarithromycin [500 mg], each taken twice daily for 7 days)
Number of subjects: 1676
Study 31995688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1676
Study 31995688 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 1676
Study 31995688 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent H. pylori infection
Number of subjects: 1676
Study 31995688 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in treatment group
Number of subjects: 1676
Study 30726234 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2.0 mA for 20 minutes)
Number of subjects: 36
Study 30726234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2.0 mA for 20 minutes)
Number of subjects: 36
Study 30726234 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (2.0 mA for 20 minutes)
Number of subjects: 36
Study 30726234 — intervention group
Group type: EXPERIMENTAL
Intervention: All tDCS conditions (anodal, cathodal, sham)
Number of subjects: 36
Study 30243993 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Syndecan-1 levels (≥ 40 ng/mL)
Number of subjects: 512
Study 30243993 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not develop sepsis
Number of subjects: 512
Study 30243993 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed sepsis
Number of subjects: 512
Study 30243993 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Syndecan-1 status, Injury Severity Score (ISS), and total blood transfused
Number of subjects: 512
Study 27187770 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Psychiatric Management (GPM) intervention over 10 sessions
Number of subjects: 40
Study 25054648 — intervention group
Group type: COMPARATOR
Intervention: Inextensible lumbosacral orthosis (iLSO)
Number of subjects: 98